All In Biotech

Drug Trial Radar · NCT05274893

A Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer

A Randomized, Open-label, Two-cycle Crossover Pharmacokinetic Comparison Study of SYHX2011 and Abraxane® in Patients With Advanced Breast Cancer

Last checked: Nov 19, 2026Latest source record: Mar 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

28

Planned (sponsor's estimate)

Start

Mar 31, 2022

Primary completion

Sep 30, 2022

Study completion Oct 30, 2022

Sponsor

Sponsor type
Industry
First posted
Mar 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, pharmacokinetic comparison study of SYHX2011 and Abraxane® in patients with advanced breast cancers after single IV infusion.

Conditions

  • Advanced Breast Cancer

Interventions

  • SYHX2011 and Abraxane®Drug

    IV infusion, 260 mg/m\^2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: From time zero up to 72 hours post-dose
  2. AUC0-tTime frame: From time zero up to 72 hours post-dose
  3. AUC0-∞Time frame: From time zero up to 72 hours post-dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.